

GODIF Newsletter September to November 2022

Thank you for committing to the GODIF trial!


Dear friends and colleagues,

We are happy to inform you that the results from the first interim analysis found a potentially clinically important and statistically significant difference between the furosemide group and the placebo group in fluid balance. Data on the dosage of trial drugs and protocol violations were also reviewed and the Data Monitoring Committee found excellent protocol compliance. **The recommendation was to continue the trial and recruitment without alteration.** Thank you so much for your hard work!



The status of the GODIF trial is that we have 15 active sites – 12 sites in Denmark, 2 sites in Norway, and 1 site in Finland. We are welcoming Herlev and Gentofte ICU in Denmark. GODIF has been approved in Iceland – congratulations! We are looking forward to the collaboration.

The recruitment is as follows:





New documents for your site master file.

An updated document for case money

New documents will always be attached to the newsletter send out four times a year.

1-year follow-up has started at several sites and is going well. Please notice that we use the new MoCA-mini which is a bit different from the former versions. Instructions can be found at the homepage. If none of the members of your research staff involved in the GODIF trial has a MoCA certificate - please get in touch with the coordinating centre when the time is near for you to start 1-year follow-up.

The Coordinating Center is always available on the
GODIF hotline: +45 48 29 67 73
Mail: godif@cric.nu
www.cric.nu/godif/
Kind Regards form the GODIF team
Morten (Sponsor) and Sine (Coordinating Investigator)

All the best,

Morten and Sine

